The multi-center clinical study evaluated the device infection and mechanical complication rates for 1,000 patients during the 12 months after they underwent CIED replacement procedures.
According to the study, the Citadel/Centurion cohort at the 90-day follow-up had 95 percent fewer major CIED infections than the pre-defined control cohort. Also, there were only 20 deaths during the period of the study, none related to the use of AIGISRx Antibacterial Envelope.
More Articles on TYRX:
Study: Antibacterial Envelope Reduces SSIs Following Cardiac IED Implantation
Survey: Majority of CEOs Believe Their Influence Can Reduce CIED Infections, Costs
TYRX Announces First Implantation of Antibacterial Stabilization Device
